Table 21

Sitagliptin or placebo added to two oral hypoglycemic agents

Author, yearChange in A1c from baseline at (%)Change in FPG from baseline at (mg/dL)Change in PPG from baseline at (mg/dL)Percent achieving A1c <7%Change in weight from baseline at (kg)Percent requiring rescue medication (%)
24 weeks24 weeks24 weeks24 weeks24 weeks24 weeks
S/G/MP/G/MS/G/MP/G/MS/G/MP/G/MS/G/MP/G/MS/G/MP/G/MS/G/MP/G/M
Hermansen, 2006a−0.59b+0.3−7.8b+12.9−21.3+15.822.61.0+0.4−0.7NRNR
a

Note: this trial also included 2 other treatment arms: glimepiride alone, glimepiride plus metformin.

b

P<0.001 compared with P/G/M.

Abbreviations: S/G/M, sitagliptin added-on to glimepiride and metformin; P/G/M, placebo added-on to glimepiride and metformin.

Note: this trial also included 2 other treatment arms: glimepiride alone, glimepiride plus metformin.

P<0.001 compared with P/G/M.

From: Results

Cover of Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus
Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet].
Norris SL, Lee NJ, Severance S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.